Key Takeaways Face/neck: NB-UVB or excimer + tacrolimus 0.1% is first-line; consider label-eligible topical JAK for added speed in limited […]
Key Takeaways First-line on face/neck: calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) as steroid-sparing agents. Backbone for generalized disease: NB-UVB
Key Takeaways Targeted therapy ideal for focal lesions, active edges, and facial/neck sites; enables high local dose while sparing uninvolved
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo; best outcomes on face/neck, slower on acral sites. Typical schedule 2–3×/week for 24–48
